Neuropsychiatric symptoms, such as depression and anxiety are more frequent in women than men. Various factors, such as genetic predisposition, psychosocial vulnerability, excessive stress and somatic diseases may explain gender differences. Moreover a strong association in the precipitation of symptoms seem to be related to the female reproductive cycle: premenstrual tension syndrome, postpartum depression or climacteric depression. These indicated the influence of hormonal fluctuations on the brain. Estrogen modulates several neurotransmitters, has direct effect on neurons by stimulating axonal sprouting, including vasodilatation. These findings lead to the theory that neuropsychiatric symptoms at menopause may be associated with declining estrogen levels and hormone therapy may help in appropriate cases. 
and risk of developing dementia doubles every 5 years after the age of 65. Approximately 7% of people aged over 65 years are affected, increasing to at least 20% in people aged 80 years and over. It may exceed 50% in those over 90. In 2006, there were 26.6 million sufferers from dementia worldwide. Alzheimer's disease (AD) is predicted to affect 1 in 85 people globally by 2050 presently it is estimated that 3.7 million Indians aged over 60 years have dementia-2.1 million women and 1.5 million men. Prevalence of dementia is 0.6 to 3.5% in rural India and 0.9 to 4.8% in urban India.
Causes
Dementia is caused by damage to brain cells and different types of dementias are associated with parti cular type of brain cell damage in particular regions of brain. Dementia is not caused by a single factor. Its presentation can be mixed. It often coexists with other conditions. Generally individual diseases have distinct clinical presentations because they affect specific areas of the brain in different ways. Depending on the underlying pathology, the illness may be reversible, static or most commonly progressive. 2 Alzheimer's disease accounts for 60 to 80% of cases of dementia. Vascular dementia, which occurs after a stroke, is the second most common that can cause symptoms of dementia, including some, that are reversible, such as thyroid problem and vitamin deficiencies (Table 1) .
Symptoms
Symptoms of dementia can vary greatly. At least two of the following core mental functions must be signi ficantly impaired to be considered dementia:
• Memory • Communication and language • Ability to focus and pay attention • Reasoning and judgment • Activities of daily living • Visual perception.
Many dementias are progressive if a person is expe riencing memory difficulties or other changes in thinking skills, this should not be ignored. Professional neuropsychological, tests aided by brain scans, may detect a treatable condition.
Even if symptoms of dementia are seen, early diag nosis allows a person to get the maximum benefit from available treatments and provides an opportunity to plan for the future.
IMPACT OF DEMENTIA
The average life expectancy of a person with dementia is 3 to 7 years after the diagnosis is made, although diag nosis often occurs some years after first onset of symp toms. It is the fourth most common cause of death.
After heart disease, cancer and stroke. The World Health Organization (WHO) recognizes dementia as one of the major causes of disability worldwide. It causes significant distress to patient, their caregivers and families and has an enormous impact on society. 3 Most people with demand live in the community and require a range of supportive services and in the longterm they are likely to require residential or nursing home care.
It is important to stress that although cognitive impair ment is a central feature of dementia, psychological and behavioral changes are also common and important symptoms. These frequently cause caregiver stress and are major factors leading to hospital admission and/or institutional care. Women have a central role in providing care and support to people with dementia, either as a member of a family or as a voluntary or aid caregiver.
Effect an patient: It includes distress and symp toms of illness, changes within the home/family, increased dependency on others, decreased indepen dence (e.g. driving), move into institutional care (financial implica tions), complications of treatments used for symptom, management (e.g. falls, fractures, hyperprolactinemia, osteoporosis cerebrovascular disease), etc.
Caregivers: Imposes significant burden, risk to mental health (particularly, depression) and physical health (e.g. due to physical intervention, such as lofting /moving), as a caregiver, social isolation, fear/uncertainly, loneliness loss of intimacy/reciprocity, grieving, stigmatization, disruption of family life, decreases quality of life, financial loss, etc.
ALZHEIMER'S DISEASE
Alzheimer's disease (AD) is a major cause of progressive dementia. Alzheimer's disease is associated with cerebral atrophy most market in the frontotemporal asso ciation cortices. Microscopically, it typically shows neurofibrillary tangles and extracellular plaques of beta amyloid proteins. In AD, Tau protein gets hyper phosphorylated creating neurofibrillary tangles and disintegrating neuron's transport system. Beta amyloid is a fragment of amyloid precursor protein (APP) which is critical to neuronal growth, survival and post injury repair. This leads to degeneration of the cholinergic neurons resulting in deficiency of acetylcholine which has a role in cognition. Scientists consider the time between initial brain change of AD and symptoms of advanced AD to represent the 'continuum' of AD.
Prevalence
Alzheimer's disease is the fourth leading cause of death in asiapacific region. For india, dementia mortality rate is 13.5 per 100000 males and 11.1 per 100000 females. Mean life expectancy following diagnosis is approximately 7 years. Other coincident diseases, such as heart problems, diabetes, alcohol abuse, are also related. With shortened survival in aging demographics and memory study (ADAMS). A cohort study of individuals born before 1954 in USA. Prevalence of AD was 71.5% in women and 28.5% in men.
Risk Factors
• Age: Approximately 1 in 20 people over the age of 65 will develop AD.
• Gender: Women appear to be at high risk for AD than • Are men OR, confidence interval (CI), 1.16 to 2.10 • Family history; risk of developing AD at an earlier age is higher 
Caregiver Care
Diagnosis of dementia sets in motion profound life changes that effect selfesteem, autonomy, interpersonal relation ships, employment income, medical care, residential decision and future plans. 6 Patients with dementia require with daily living and eventually long term supportive care. The caregivers also need help and support. 
MENOPAUSE, HORMONE THERAPY AND ALZHEIMER'S DISEASE
Dementia is viewed as end stage disease and it must be distinguished from agerelated cognitive decline.
Overall women are at extreme risk compared with men for depression and AD but not for neurovascular dementia. Common place symptoms that accompany the menopause transition namely hot flushes, sleep disturbances and imtability suggest that parts of the brain sub serving function other than solely reproductive, are critically impacted by the presence or absence of sex steroids. 8 Estrogen modulate synaptic density neuronal and glial viability and neurotransmitter systems that underpass cognitive, emotional and motor function. 9 It increases the cerebral blood flow and has an antioxidant and antiinflammatory effect. Estrogen therapy is not currently recommended for reducing risk of dementia developing in postmenopausal women or retarding the progress of diagnosed AD. 10 Although limited data suggests that early use of hormone therapy (HT) in the menopause may be associated with diminished risk of later dementia. Women's health initiative memory study (WHIMS) trial of estrogen and a progestin and estrogen alone, were two large randomized controlled trials (RCT) conducted in older menopausal women. 11 These studies showed no benefit and potential harm in administering HT to older postmenopausal women. Risk of cognitive decline was particularly increased over the age of 65 years and adverse effect of conjugated equine estrogens (CEEs) were more pro nounced in women with lower cognitive function at base line and among women receiving MPP + E compared to those receiving E alone.
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In WHIMS after exclusion of women with baseline impairment hazard ratios (HR) was 1.77 (95% CI, 0.74-4.23, p = 0.20). In E alone trial and 2.1 (95% CI, 1.25-3.84; p = 0.006) in pooled in trials. In estrogen alone trial, mild cognitive impairment was diagnosed in 76 participants in CEE group and 58 in placebo group [HR, 1.34 (95% CI, 0.95-1.89)]. In E + P group HR was similar according to WHIMS, there may exist a critical window for neuroprotection. Henderson et al, in 2007 , reanalyzed the data from WHIMS. All cause dementia was significantly less likely to develop in women reporting prior HT. In 106 pooled cases adjusted HR was 0.54 (95% CI, 0.16-0.85), for those with nonalzheimer dementia HR was 0.75 (95% CI, 0.36-1.39). Case control studies of women who underwent oophorectomy before menopause, have recently shown small risk of dementia and parkinsonism 813 women who underwent unilateral oophorectomy and 676 who underwent bilateral oophorectomy before onset of menopause compared with 1,472 referent women, HR for cognitive impairment was 1,46 (95/CI, 1.13-1.90) adjusted for education type of interview and history of dementia. Women experiencing verbal memory changes at menopause can be advised there is no apparent association between verbal memory change and global cognitive decline. Very few clinical trial support use of estrogen therapy (ET) for cognitive benefits, when initiated immediately after surgical menopause. 13 To date clinical trials of ET have demonstrated no substantial effect of episode memory or executive functioning. Natural menopause has a significant but small effect on some aspects of cognitive that may be time limited. This effect is not explained by menopausal symptoms. In study of women's health across the nation who initiated HT/ oral contraceptives (OC) before their final menstrual and then discontinued had a beneficial effect whereas women who initiated hormones after final menstrual period had diminished effect on cognitive function. The estimate of dementia cases attributed to HT was 12 per 10,000 persons per year ET use and 23 per 10,000 per year of estrogen progestin therapy (EPT) use.
Cache county study, 14 showed that there is reduction in AD risk in HT users who initiated treatment within 5 years after menopause. This reduction was greater with sustained use of 10 years or more keeping in line with the theory of window of opportunity. Nonoral route of delivery of estradiol that approximate 100 pg/ml or lower may minimize risk of vascular compromise and stork while enchasing synaptogenesis, neural metabolism, and neurotransmission and brain plasticity, conferring neurotransmission. Cognitive preservation was more strongly associated with bio available estradiol, estrogen receptor (ER) alpha agonist, than with total estradiol. 15 Selective estrogen receptor modulators (SERMs), aromatase inhibitors or mainly ER beta agonist, like phytoestrogens cannot garner complete protection. By the time dementia tors or mainly ER beta agonists, like phytoestrogens cannot garner complete is clinically evident, there is significant loss of neurons and glia and it is unrealistic to expect HT to revive dead tissue or restore brain architecture. For best preservation of memory and cognition women should be advised about the importance of good overall health, good cardiac and vascular health, exercise, maintenance of active mind, avoidance of excessive, alcohol consumption measures to reduce risk of diabetes and hypertension. Hormone therapy is not indicated for neuroprotection.
Genetics may be responsible for only a third of AD risk, with the rest dependent on modifiable factors, according to the MacArthur studies of successful aging. There may be a major role for lifestyle medication in preventing AD, exercise, mental stimulation, stress management and nutrition. 
JSAFOMS

MENTAL STIMULATION
Mentally stimulating activities and certain braintraining programs are in the longterm associated with lower brain amyloid levels a decreased risk for AD engage in lifelong learning.
Stress Management
Stress is known to effect cognitive function. Sapoisky et al have shown in animal studies that stress is linked with memory impairment and reduced brain size; specifically, glucocorticoids released during stress appear to impair neuronal plasticity and dendrite atrophy, particularly in the hippocampus, stress hormones impair prefrontal cortical functioning, affecting mental affecting mental flexibility and attention. Date indicates that AD, depression and additionaly relaxation, meditation affects biomarkers of inflammation and telomerase activity positively.
NUTRITION
Weight management and nutrition also play major roles in brain health. Several studies support an association between being overweight and increased dementia risk, including recent twin study controlled for sex, education, diabetes, hypertension, stroke, and heart disease. Concurrent work found that cognitive function improved significantly in obese patients who underwent bariatric surgery. Mediterranean diets high in omega3 fatty acids improved working memory and reduce risk for mild cognitive impairment, minor neurocognitive disorder and AD. Antioxidantrich fruits and vegetables improve cognition while refined sugars and fats impair it. Areas with turmeric and curryheavy diets, such as lndia have lower rate of AD. Another study is looking at pomegranate extract, as daily consumption is associated with improved verbal memory.
